SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–FDA filing acceptance announced for Enspryng (satralizumab) in MOGAD, a rare neurological disease.
Month: September 2026
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–FDA filing acceptance announced for Enspryng (satralizumab) in MOGAD, a rare neurological disease.
MONTEVARCHI, Italy–(BUSINESS WIRE)–Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company will highlight key business and technical milestones in the UK market at the Solar & Storage Live UK 2026 trade show in Birmingham from September 22-24. In the wake of a cross-country installer training tour and the UK market release of the Tigo GO ESS platform, Tigo will focus its 2026 trade show
MONTEVARCHI, Italy–(BUSINESS WIRE)–Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company will highlight key business and technical milestones in the UK market at the Solar & Storage Live UK 2026 trade show in Birmingham from September 22-24. In the wake of a cross-country installer training tour and the UK market release of the Tigo GO ESS platform, Tigo will focus its 2026 trade show
MARSEILLE, France–(BUSINESS WIRE)—- $IPH #ADC–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026. Participants in the call will be: Jonathan Dickinson, Chief Executive Officer Markus Jensen, Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Op
MARSEILLE, France–(BUSINESS WIRE)—- $IPH #ADC–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026. Participants in the call will be: Jonathan Dickinson, Chief Executive Officer Markus Jensen, Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Op
MARSEILLE–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que la Société tiendra une conférence téléphonique le jeudi 17 septembre 2026 à 14h00 CEST / 8h00 EDT, pour présenter son activité au premier semestre 2026. La conférence sera animée par : Jonathan Dickinson, Directeur Général Markus Jensen, Vice-président, Directeur Médical Yannis Morel, Vice-président exécutif, Directeur des Opérations Frédéri
MARSEILLE–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que la Société tiendra une conférence téléphonique le jeudi 17 septembre 2026 à 14h00 CEST / 8h00 EDT, pour présenter son activité au premier semestre 2026. La conférence sera animée par : Jonathan Dickinson, Directeur Général Markus Jensen, Vice-président, Directeur Médical Yannis Morel, Vice-président exécutif, Directeur des Opérations Frédéri
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKIO: 4519) anunció hoy que el Dr. Kunihiro Hattori (ex Senior Fellow de Chugai), el Dr. Takehisa Kitazawa (subdirector de la División de Investigación de Chugai) y el Dr. Tomoyuki Igawa (director de la División de Investigación de Chugai), quienes lideraron el desarrollo de Hemlibra (emicizumab), un tratamiento para la hemofilia A, recibieron el Lasker-DeBakey Clinical Medical Research Award, uno de los máximos reconocimientos científic
BENGALURU, India & PUNE, India–(BUSINESS WIRE)– #AI–Neural Concept today announced the establishment of a direct commercial presence in India, with teams based in Bengaluru and Pune.